N-Arachidonylglycine是一种强效的GPR18激动剂，EC50值为44.5nM。
Cas No.:179113-91-8
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
N-Arachidonylglycine is a potent GPR18 agonist with an EC50 value of 44.5nM [1]. N-Arachidonylglycine acts an endogenous inhibitor of GLYT2 (IC50=3μM) that has the capacity to modulate nociception [2]. N-Arachidonylglycine can increase the intracellular Ca²⁺ level in neurons by activating GPR92[3]. N-Arachidonylglycine has been widely used to promote the production of reactive oxygen species in liver mitochondria and the release of cytochrome c[4].
In vitro, N-Arachidonylglycine treatment (10µM) for 3 days significantly inhibited the secretion of IFNγ and IL-17 in CD4+ T cells[5]. Treatment with 10nM N-Arachidonylglycine for 24 hours significantly promoted the proliferation of BV-2 cells and activation of the MAPK pathway[6].
In vivo, N-Arachidonylglycine treatment via a single intrathecal injection (700nmol; 20µl) for 6h can alleviate mechanical hyperalgesia and thermal hyperalgesia induced by intratibial injection of Freund's complete adjuvant (FCA) in rats[7].
References:
[1] McHugh D, Page J, Dunn E, et al. Δ9‐Tetrahydrocannabinol and N‐arachidonyl glycine are full agonists at GPR18 receptors and induce migration in human endometrial HEC‐1B cells[J]. British journal of pharmacology, 2012, 165(8): 2414-2424.
[2] Edington A R, McKinzie A A, Reynolds A J, et al. Extracellular loops 2 and 4 of GLYT2 are required for N-arachidonylglycine inhibition of glycine transport[J]. Journal of Biological Chemistry, 2009, 284(52): 36424-36430.
[3] Yoon J M, Moon M J, Hwang J I, et al. Identification of farnesyl pyrophosphate and N-arachidonylglycine as endogenous ligands for GPR92[J]. Journal of Biological Chemistry, 2008, 283(30): 21054-21064.
[4] Zaccagnino P, Saltarella M, D'Oria S, et al. N-arachidonylglycine causes ROS production and cytochrome c release in liver mitochondria[J]. Free Radical Biology and Medicine, 2009, 47(5): 585-592.
[5] Meadows A M, Han K, Singh K, et al. N-arachidonylglycine is a caloric state-dependent circulating metabolite which regulates human CD4+ T cell responsiveness[J]. Iscience, 2023, 26(5).
[6] McHugh D, Hu S S J, Rimmerman N, et al. N-arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptor[J]. BMC neuroscience, 2010, 11(1): 44.
[7] Succar R, Mitchell V A, Vaughan C W. Actions of N-arachidonyl-glycine in a rat inflammatory pain model[J]. Molecular pain, 2007, 3: 1744-8069-3-24.
N-Arachidonylglycine是一种强效的GPR18激动剂，EC50值为44.5nM[1]。N-Arachidonylglycine作为一种内源性GLYT2抑制剂（IC50=3μM），具有调节伤害感受的能力[2]。N-Arachidonylglycine可通过激活 GPR92增加神经元内Ca2+水平[3]。N-Arachidonylglycine已被广泛用于促进肝线粒体中活性氧的产生和细胞色素c的释放[4]。
在体外，10μM的N-Arachidonylglycine处理CD4⁺ T细胞3天，显著抑制了IFNγ和IL-17的分泌[5]。10nM的N-Arachidonylglycine处理BV-2细胞24小时，显著促进了细胞增殖和MAPK通路的激活[6]。
在体内，单次鞘内注射700nmol（20µl）N-Arachidonylglycine持续6小时，可减轻胫骨内注射Freund's complete adjuvant (FCA)诱导的大鼠机械性痛觉过敏和热痛觉过敏[7]。
| Cell experiment [1]: | |
Cell lines | BV 2 cells |
Preparation Method | BV 2 cells were seeded in 96-well plates at a density of 1×104 cells in DMEM medium with 1% (v/v) fetal bovine serum (FBS), 100U/ml penicillin, and 100µg/ml streptomycin in a humidified atmosphere containing 5% CO2 for 24h. Cells were treated with different concentrations of N-Arachidonylglycine (0.001, 0.01, 0.1, and 1nM) for 24h, and the cell proliferation was measured. |
Reaction Conditions | 0.001, 0.01, 0.1, and 1nM; 24h |
Applications | N-Arachidonylglycine treatment significantly enhanced cell proliferation of BV 2 cells in a dose-dependent manner. |
| Animal experiment [2]: | |
Animal models | Male Sprague-Dawley rats |
Preparation Method | Male Sprague-Dawley rats (160-180g) were housed in a room with controlled temperature (21-23°C), humidity (55-60%), and lighting (12h light/dark cycle) and were supplied with water. The following surgical procedures were carried out under isoflurane (1-3% in O2) anaesthesia. Chronic polyethylene lumbar intrathecal catheters were inserted between vertebrae L5-6, advanced 3cm rostrally, and exteriorized via the occipital region. Intrathecal injections of N-Arachidonylglycine and HU-210 were made in gently restrained animals via the exteriorized catheter (20μl of agent, followed by 15μl flush of saline to allow for dead-space in the catheter). For the inflammatory pain model, 0.15ml of FCA was injected subcutaneously into the plantar surface of the left-hand paw. The behaviors of mechanical pain hypersensitivity and thermal pain hypersensitivity in rats were analyzed within 6 hours. |
Dosage form | 00nmol (20µl) for once; i.t. |
Applications | N-Arachidonylglycine treatment alleviated mechanical hyperalgesia and thermal hyperalgesia induced by FCA. |
References: | |
| Cas No. | 179113-91-8 | SDF | |
| 别名 | N-Arachidonyl Glycine, NAGly | ||
| 化学名 | 2-((5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenamido)acetic acid | ||
| Canonical SMILES | O=C(CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC)NCC(O)=O | ||
| 分子式 | C22H35NO3 | 分子量 | 361.52 |
| 溶解度 | 50mg/mL in ethanol, 10mg/mL in metyle acetate, 15mg/mL in DMSO, 20mg/mL in DMSO | 储存条件 | Store at -20°C,stored under nitrogen |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.7661 mL | 13.8305 mL | 27.661 mL |
| 5 mM | 553.2 μL | 2.7661 mL | 5.5322 mL |
| 10 mM | 276.6 μL | 1.383 mL | 2.7661 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: Solid-liquid mixture
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet